Commercializing breakthrough advances in inflammation science. MORE
Antibe Therapeutics is a publicly traded biotechnology company exploiting groundbreaking advances in inflammation science.
Pursuing blockbuster opportunities for safer, non-addictive therapeutics for pain and inflammation. MORE
We are harnessing our proprietary hydrogen sulfide-based drug platform to deliver safer, non-addictive therapeutics for pain and inflammation.
Tapping the therapeutic potential of hydrogen sulfide. MORE
Our drug platform draws on 20 years of research into the substantial beneficial effects of hydrogen sulfide in a wide range of clinical disorders.
Informing our investors. MORE
Review the Investor Dashboard for share price, investor presentation, financial statements and regulatory filings.
Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results
Antibe Announces Closing of Public Offering
Antibe Therapeutics Announces Filing of Final Short Form Prospectus
Antibe Therapeutics Announces Size of Offering
Antibe Therapeutics Announces Offering of Units
Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results
Antibe Therapeutics Announces Results of Annual General and Special Meeting
Antibe Therapeutics Announces CEO Letter to Shareholders
Antibe Therapeutics Unveils Lead Indication for ATB-352, a Potent, Non-Addictive Analgesic for Severe Pain